MAGEA3 and acute myeloid leukemia: In addition, DCP-001 vaccination of AML patients was also shown to induce immune responses towards dominant TAAs not expressed by DCP-001 itself such as NY-ESO-1 and MAGE-A3, suggesting the spreading of the immune response induced by the vaccine towards patient tumor-specific antigens [7].